Boehringer calls off €627M deal with GSK spin­out, pass­ing on schiz­o­phre­nia drug op­tion

5 years ago
Deals

Vivek Ra­maswamy’s Der­ma­vant team looks to take on Am­gen’s $13.4B pso­ri­a­sis con­tender Ote­zla with a promis­ing ...

5 years ago
R&D

Rid­ing on ear­ly can­cer de­tec­tion fren­zy, Freenome scores $270M to push liq­uid biop­sy tech be­yond col­orec­tal can­cer

5 years ago
Financing

Ae­tion push­es Se­ries B to $82M as pan­dem­ic puts re­al-world ev­i­dence un­der the spot­light

5 years ago
Financing
Coronavirus

Kin­nate gets $98M Se­ries C to push pre­ci­sion on­col­o­gy drugs to the clin­ic

5 years ago
Financing

Te­va charged — again — for al­leged role in fix­ing gener­ic drug prices, this time by the De­part­ment of Jus­tice

5 years ago
Pharma

Covid-19 roundup: Eu­ro­pean vac­cines lob­by push­ing for li­a­bil­i­ty pro­tec­tion; VBI vac­cines to prep hu­man tri­als

5 years ago
Coronavirus

No­var­tis finds a third-gen­er­a­tion scion to an ag­ing Gleevec, suc­cess­ful­ly tak­ing on a Pfiz­er ri­val for last-chance ...

5 years ago
R&D

Black­stone bankrolls sup­ply chain play­er's deal spree with $275M

5 years ago
Deals

ATAI adds MD­MA biotech to grow­ing list of psy­che­del­ic mak­ers; Aca­dia adds $52.5M up­front pain buy­out

5 years ago
News Briefing

A small VC group ex­pands its hunt for in­spired biotech founders in need of seed cash

5 years ago
People
Financing

Troy Wil­son re­cruits As­traZeneca vet to steer Ku­ra's late-stage piv­ot

5 years ago
People

Agios just sold off the roy­al­ty rights for $255M, but Bris­tol My­ers says Id­hi­fa was a bust in PhI­II. Now what?

5 years ago
R&D

Ovid gets quick raise off PhII seizure re­sults. Can the re­sults hold up against GW?

5 years ago
Financing
R&D

Covid-19 roundup: Bio­gen con­fer­ence is tied to tens of thou­sands of Covid-19 cas­es; FDA chief Stephen Hahn walks back ...

5 years ago
Coronavirus

Ex­clu­sive: We asked for bio­phar­ma's opin­ion about the plas­ma EUA. The in­dus­try of­fered a dou­ble-bar­reled re­sponse

5 years ago
FDA+
Coronavirus

Take­da inks up to $500M col­lab­o­ra­tion with ex­tra-cel­lu­lar ma­trix biotech for NASH

5 years ago
R&D

Ab­b­Vie op­tions in­te­grin-based com­pounds from Mor­phic, paving way for po­ten­tial fi­bro­sis treat­ments

5 years ago
Deals

Tri­ci­da 'fore­shad­owed' its CRL — but shares still fall with fear of years-long de­lay

5 years ago
R&D
FDA+

Con­nect Bio­phar­ma snags $115 mil­lion in Se­ries C to de­vel­op ar­se­nal of im­mune mod­u­la­tors

5 years ago
Financing
China

Odonate an­nounces 'pos­i­tive' re­sults but faces in­vestor back­lash; Aslan is once again re­cruit­ing clin­i­cal tri­al ...

5 years ago
News Briefing

Vir en­lists Covid-19 an­ti­body ri­val for can­cer, in­fec­tious dis­ease dis­cov­ery work

5 years ago
Deals

On­cono­va re­ports PhI­II flop, putting high-risk MDS pro­gram on the chop­ping block

5 years ago
R&D

Bris­tol My­ers hun­kers down at the deals ta­ble, ex­e­cut­ing a new I/O play in biotech buy­out

5 years ago
Deals
First page Previous page 808809810811812813814 Next page Last page
A service from the Financial Times